Matthew Holt Net Worth

The estimated Net Worth of Matthew S. Holt is at least $131 million dollars as of 12 February 2015. Mr. Holt owns over 1,070,166 units of Avantor stock worth over $130,779,505 and over the last 10 years he sold AVTR stock worth over $0. In addition, he makes $0 as Director at Avantor.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Holt AVTR stock SEC Form 4 insiders trading

Matthew has made over 1 trades of the Avantor stock since 2015, according to the Form 4 filled with the SEC. Most recently he bought 1,070,166 units of AVTR stock worth $12,841,992 on 12 February 2015.

The largest trade he's ever made was buying 1,070,166 units of Avantor stock on 12 February 2015 worth over $12,841,992. On average, Matthew trades about 97,288 units every 0 days since 2015. As of 12 February 2015 he still owns at least 4,859,885 units of Avantor stock.

You can see the complete history of Mr. Holt stock trades at the bottom of the page.

Matthew Holt biography

Matthew S. Holt is Director of the Company. Mr. Holt has served on our Board since 2010 and is currently the Chair of the Compensation and Human Resources Committee. Mr. Holt is a Managing Director of New Mountain Capital, LLC, a private equity investment firm based in New York, New York. He serves as the Deputy Head of Private Equity at New Mountain and focuses on growth buyouts across a range of industries including healthcare products, health technology, materials and infrastructure. He previously worked in the Mergers and Acquisitions Group at Lehman Brothers, a financial services firm, from 1999 to 2001. He currently serves as Lead Director or Chairman of CIOX Health, Cytel, emids, Ontario Systems, Revint Solutions, Signify Health, W20 and Zep, Inc. He also serves as a director of Aceto, Topix Pharmaceuticals, Gelest and TRC Companies. Mr. Holt has previously served as Lead Director of Bellerophon Therapeutics, Inc., Convey Health Solutions, Inc., Equian LLC, Ikaria, Inc., Nusil Technology LLC, and Director of MailSouth. Mr. Holt earned an A.B. in English and American Literature and Language from Harvard College.

How old is Matthew Holt?

Matthew Holt is 43, he's been the Director of Avantor since 2010. There are 28 older and 3 younger executives at Avantor. The oldest executive at Avantor Inc. is Rajiv Gupta, 74, who is the Chairman of the Board.

What's Matthew Holt's mailing address?

Matthew's mailing address filed with the SEC is C/O SIGNIFY HEALTH, INC., 4055 VALLEY VIEW LN, SUITE 700, DALLAS, TX, 75244.

Insiders trading at Avantor

Over the last 6 years, insiders at Avantor have traded over $3,149,576,044 worth of Avantor stock and bought 27,800 units worth $584,024 . The most active insiders traders include Mountain Investments Iii, L..., Jo Natauri et Sachs & Co. Llc Stone Bridg.... On average, Avantor executives and independent directors trade stock every 21 days with the average trade being worth of $48,107,115. The most recent stock trade was executed by Steven W Eck on 5 September 2024, trading 3,525 units of AVTR stock currently worth $88,337.

What does Avantor do?

based in center valley, pa (usa), avantor performance materials manufactures and markets high-performance chemistries and materials around the world under several respected brand names, including the j.t.baker®, macron fine chemicals™, rankem™, benesphera™, and poch™ brands. avantor products are used in a wide range of industries. our life sciences solutions are used in pharmaceutical production, laboratory research for academic, industry and quality control, and in medical lab testing. our electronics solutions are used in the manufacturing of semiconductors. for additional information please visit www.avantormaterials.com

Complete history of Mr. Holt stock trades at Bellerophon Therapeutics Inc, Avantor et Signify Health

Avantor executives and stock owners

Avantor executives and other stock owners filed with the SEC include:

• Michael Stubblefield,
  President, Chief Executive Officer, Director
• Thomas Szlosek,
  Chief Financial Officer, Executive Vice President
• Michael Stubblefield,
  Pres, CEO & Director
• Gerard Brophy,
  Executive Vice President - Biopharma Production
• Devashish Ohri,
  Executive Vice President - AMEA
• Frederic Vanderhaegen,
  Executive Vice President - Americas and Europe
• Thomas A. Szlosek,
  Exec. VP & CFO
• Frederic Vanderhaegen,
  Exec. VP of Americas & Europe
• Dr. Gerald Brophy Ph.D.,
  Exec. VP of Biopharma Production
• Michael Wondrasch,
  Exec. VP & Chief Information Officer
• Rajiv Gupta,
  Chairman of the Board
• Jonathan Peacock,
  Independent Director
• Christi Shaw,
  Independent Director
• Rakesh Sachdev,
  Independent Director
• Juan Andres,
  Independent Director
• Gregory Summe,
  Independent Director
• Michael Severino,
  Independent Director
• Jo Natauri,
  Director
• Andre Moura,
  Director
• Matthew Holt,
  Director
• Steven Eck,
  Senior Vice President, Chief Accounting Officer
• Mark Murray,
  Executive Vice President of the Biomaterials and Advanced Technologies Platform
• Sven Henrichwark,
  Executive Vice President of APAC
• Tanya Foxe,
  Executive Vice President - Global Operations and Supply Chain
• Christophe Couturier,
  Executive Vice President - Services, Strategy and Business Transformation
• James Bramwell,
  Executive Vice President - Strategic Partners
• Justin Miller,
  Executive Vice President, General Counsel, Secretary
• Michael Wondrasch,
  Executive Vice President, Chief Information Officer
• Eric McAllister,
  Chief Human Resource Officer, Executive Vice President
• Allison K. Hosak,
  Sr. VP of Global Communications & Brand
• Justin M. Miller Esq.,
  Exec. VP, Gen. Counsel & Sec.
• Tommy J. Thomas CPA,
  VP of Investor Relations
• Steven W. Eck,
  Sr. VP, Corp. Controller & Chief Accounting Officer
• Sheri Lewis,
  Exec. VP, Global Operations & Supply Chain
• Lan Kang,
  Director
• John Carethers,
  Director
• Sachs & Co. Llc Stone Bridg...,
  
• Sachs & Co. Llc Stone Bridg...,
  
• Sheri Lewis,
  EVP, Global Ops & Supply Chain
• Mountain Investments Iii, L...,
  
• Mala Murthy,
  Director
• Brittany Hankamer,
  EVP, Chief HR Officer
• Randy Lee Stone,
  EVP, Laboratory Solutions
• Corey Walker,
  President Laboratory Solutions
• Ashish Kulkarni,
  See Remarks
• Sachs & Co. Llcgoldman Sach...,
  
• Meghan Henson,
  EVP, Chief HR Officer
• Thomas Connolly,
  Director
• Joseph R Massaro,
  Director
• Kitty Sahin,
  EVP, Strategy&Corp Development
• Claudius Sokenu,
  EVP, Chief Legal & Compliance
• R. Brent Jones,
  EVP, Chief Financial Officer
• Benoit Gourdier,
  EVP, Biopharma Production